ORAGENICS INC financial data

Symbol
OGEN on NYSE
Location
Sarasota, FL
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 07 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity 165% % 170%
Return On Equity -572% % 27%
Return On Assets -216% % 56%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 4,168,223 shares -66%
Common Stock, Shares, Outstanding 4,127,173 shares -56%
Entity Public Float $4,740,189 USD -29%
Common Stock, Value, Issued $4,127 USD -56%
Weighted Average Number of Shares Outstanding, Basic 1,560,909 shares 617%
Weighted Average Number of Shares Outstanding, Diluted 1,560,909 shares 617%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $3,387,315 USD -75%
General and Administrative Expense $6,832,319 USD 5%
Operating Income (Loss) $10,219,634 USD 49%
Nonoperating Income (Expense) $685,108 USD -2146%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $10,334,078 USD 49%
Net Income (Loss) Attributable to Parent $10,904,742 USD 45%
Earnings Per Share, Basic 20 USD/shares 83%
Earnings Per Share, Diluted 20 USD/shares 83%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $11,403,766 USD 263%
Assets, Current $12,705,544 USD 209%
Assets $12,705,544 USD 144%
Accrued Liabilities, Current $202,834 USD -8.9%
Liabilities $2,874,108 USD 35%
Retained Earnings (Accumulated Deficit) $224,341,789 USD -5.1%
Stockholders' Equity Attributable to Parent $9,831,436 USD 219%
Liabilities and Equity $12,705,544 USD 144%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $2,112,090 USD 31%
Net Cash Provided by (Used in) Financing Activities $4,668,328 USD 182%
Common Stock, Shares Authorized 350,000,000 shares 0%
Common Stock, Shares, Issued 4,127,173 shares -56%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $2,556,238 USD
Interest Paid, Excluding Capitalized Interest, Operating Activities $6,268 USD -12%
Deferred Tax Assets, Valuation Allowance $48,366,736 USD 3%
Deferred Tax Assets, Gross $48,366,736 USD 3%
Deferred Tax Assets, Operating Loss Carryforwards $41,070,043 USD 3.2%
Preferred Stock, Shares Issued 7,488,692 shares -56%
Preferred Stock, Shares Authorized 50,000,000 shares 0%
Unrecognized Tax Benefits $4,041,694 USD -3.1%
Additional Paid in Capital $234,169,098 USD 9%
Preferred Stock, Shares Outstanding 7,488,692 shares -56%
Share-based Payment Arrangement, Expense $516,049 USD -6.2%
Interest Expense $34,329 USD 126%